“…Nevertheless, the two-stage ESCC screening strategy effectively identified more EC patients while saving resources. As the number of individuals undergoing opportunistic screening increases 27 , this strategy can also be applied to follow-up monitoring and management of those who undergo baseline EC screening. Despite the rapid development of liquid biopsy and multi-omics technologies, there are currently no recommended biomarkers for EC screening 28 .…”